Guardant Health and Boehringer Ingelheim are revolutionizing cancer care with Guardant360 CDx liquid biopsy, potentially transforming NSCLC treatment.
Discover how EDX Medical Group Plc (AQSE:EDX) is revolutionising digital clinical diagnostics to predict disease risk and personalise healthcare.
Young people are increasingly diagnosed with cancer, highlighting the importance of awareness and early detection. Learn from Grayson Niemi’s journey.
Discover how EDX Medical is revolutionising digital clinical diagnostics to predict disease risk and personalise healthcare.
With the Movember campaign gaining momentum, it’s an opportune time to address testicular cancer, a condition that disproportionately affects young men. Each year in Europe, over 25,000 new cases are
EDX Medical Group PLC, based in Cambridge, England, has announced a new step forward in the fight against testicular cancer by signing an exclusive agreement with mirdetect GmbH. This partnership
EDX Medical announced a new partnership, securing exclusive rights to distribute mirdetect GmbH’s M371 diagnostic test for testicular cancer. This Cambridge-based company is known for its innovative digital diagnostic tools,
Cancer remains a significant global health issue and is the second leading cause of death in the U.S., following heart disease. While many cancers are linked to lifestyle, environmental, or
Genes are sections of DNA that carry instructions for building proteins, essential for the body’s proper functioning. Changes in these genes are known as single-gene variants. Genetic testing can reveal
The Guardant Reveal liquid biopsy test has shown potential in predicting disease recurrence in patients with stage II and higher colorectal cancer (CRC), based on data from the COSMOS study,
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
